-
Diagnostics World News | For the benefit of laboratory and healthcare professionals, the American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) published joint guidelines in 2015 aimed at standardizing terminology and the classification of sequence variants uncovered through genetic testing. Understandably, in the several years since then, there have been tremendous advances in this field of molecular diagnostics such as next-generation sequencing (NGS) technologies unlocking new opportunities to understand an individual’s unique genetic makeup. Armed with these insights, healthcare providers can personalize therapeutic options for their patients with genetic diseases, helping to manage or treat them altogether.
Aug 20, 2021
-
Diagnostic World News | Researchers at Massachusetts Institute of Technology have developed a urine-based molecular assay that can both reveal the presence of cancerous proteins and pinpoint a tumor’s location. The double-duty diagnostic nanosensor could one day be of clinical value in evaluating treatment response and long-term monitoring of tumor recurrence.
Aug 17, 2021
-
Diagnostics World News | The US Food and Drug Administration (FDA) in February issued an AI and Machine Learning Software as a Medical Device Action Plan, outlining the way forward for manufacturers seeking the agency’s approval for their innovative medical devices incorporating AI.
Aug 12, 2021
-
Diagnostics World News | As the coronavirus pandemic continues, new initiatives are emerging to help fend off future pandemics including the Pandemic Sciences Centre at the University of Oxford and the Centers for Research in Emerging Infectious Diseases, a global network investigating how and where viruses and other pathogens emerge from wildlife settings.
Aug 9, 2021
-
Diagnostics World News | InterVenn closes a series C for liquid biopsy assay for immune checkpoint inhibitor response prediction, Strata advances personalized minimal residual disease (MRD) assays, Lumos Diagnostics in Australia goes public, and more.
Aug 5, 2021
-
Diagnostics World | More COVID-19 tests prove accurate for the delta variant, NVIDIA’s Cambridge-1 supercomputer builds synthetic brain images, biobank and practice acquisitions, and FDA companion diagnostic approvals for Foundation Medicine.
Aug 3, 2021
-
Diagnostics World News | As more people become vaccinated, researchers are continuing to evaluate the duration of immunity and variations in an immune response among previously infected and non-infected people, using neutralizing antibodies as their metric. This growing body of information presents critical data about COVID-19 immunity that determines when and how individuals should protect themselves from the virus. Understanding immunity levels offers global solutions for ending the COVID-19 pandemic and addressing future health crises.
Aug 2, 2021
-
Diagnostics World News | Extrachromosomal DNA (ecDNA), circles of DNA outside the chromosomes but still within the nucleus of a cell, is believed to be an important but overlooked target in the treatment of amplification-driven tumors that have up to now been uniformly resistant to anti-cancer therapies. Boundless Bio is actively exploring the genes and cellular processes that underpin some crafty maneuvers of ecDNA using a precision medicine platform called Spyglass.
Jul 29, 2021
-
Diagnostics World News | Researchers with Singapore-based longevity startup Gero have used wearable sensor data and artificial intelligence to develop digital biomarkers of longevity, stress, and resilience. The novel GeroSense biological age acceleration model is being positioned as a practical, high-quality alternative to blood tests or genomic profiling for large-scale population health studies.
Jul 27, 2021
-
Diagnostics World News | The sources of health disparities are complex, and diagnostic testing is just one waystation on what is often an exhausting trek for many patients and their families. But today’s genetic tests may not be useful across ancestral groups.
Jul 26, 2021
-
Diagnostics World News | The board members of both Sema4 and CM Life Sciences voted this week to approve the special purpose acquisition company. The resulting combined company, Sema4 Holdings Corp, will commence trading of its shares of common stock and warrants on the Nasdaq Global Select Market under the ticker symbols "SMFR" and “SMFRW” today or Monday.
Jul 23, 2021